Clinical features and prognosis of nocardiosis in patients with connective tissue diseases

Mod Rheumatol. 2021 May;31(3):636-642. doi: 10.1080/14397595.2020.1823070. Epub 2020 Oct 2.

Abstract

Objectives: To investigate the clinical features and prognosis of nocardiosis complicated by connective tissue diseases (CTDs).

Methods: We examined patients with CTDs who were diagnosed with nocardiosis from October 2004 to 2019. We retrospectively investigated patient characteristics and therapeutic outcomes. We then performed a comparison between survivors and non-survivors.

Results: Fourteen patients were examined. Underlying CTDs were systemic lupus erythematosus (28.6%), vasculitis syndrome (28.6%), rheumatoid arthritis (21.4%), adult Still disease (14.3%) and dermatomyositis (7.1%). Infected organs were lung (85.7%), brain (42.9%), skin/cutaneous lesions (28.6%) and muscle (7.1%). Disseminated infections were seen in nine patients (64.3%). At the onset of nocardiosis, all patients were given prednisolone (23.2 ± 11.9 mg/day). Only two patients (14.3%) were given TMP-SMX for prophylaxis of pneumocystis pneumonia. Relapse occurred in one patient (7.1%) and four patients (28.6%) died from nocardiosis for a cumulative survival rate at 52 weeks of 76.9%. In a comparison of survivors (71.4%) and non-survivors (28.6%), cutaneous lesions were significantly more frequent in the latter (10 vs 75%, p = .04) with an odds ratio of 27.0 (95% CI: 1.7-453.4).

Conclusion: Cutaneous lesions as a result of dissemination might be a risk factor for nocardiosis mortality in patients with CTDs.

Keywords: Connective tissue disease; Nocardia; cutaneous lesion; dissemination; nocardiosis.

MeSH terms

  • Adult
  • Anti-Bacterial Agents / adverse effects
  • Anti-Bacterial Agents / therapeutic use*
  • Arthritis, Rheumatoid / complications*
  • Female
  • Humans
  • Lupus Erythematosus, Systemic / complications*
  • Male
  • Middle Aged
  • Nocardia Infections / complications
  • Nocardia Infections / drug therapy*
  • Nocardia Infections / pathology
  • Prognosis
  • Retrospective Studies
  • Trimethoprim, Sulfamethoxazole Drug Combination / adverse effects
  • Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use*
  • Vasculitis / complications*

Substances

  • Anti-Bacterial Agents
  • Trimethoprim, Sulfamethoxazole Drug Combination